-+ 0.00%
-+ 0.00%
-+ 0.00%

Greenwich Lifesciences’ FLAMINGO-01 breast cancer immunotherapy abstract accepted for ASCO poster

PUBT·04/23/2026 10:03:08
Listen to the news
Greenwich Lifesciences’ FLAMINGO-01 breast cancer immunotherapy abstract accepted for ASCO poster
  • Greenwich LifeSciences secured acceptance of an abstract for publication with a poster presentation at 2026 ASCO Annual Meeting, covering preliminary immune-response findings from open-label non-HLA-A02 arm of Phase III FLAMINGO-01 trial for GLSI-100 in breast cancer recurrence prevention.
  • Presentation materials will be released June 1, 2026, during meeting running May 28 to June 2, 2026.
  • Preliminary readout indicated recurrence outcomes following initial dosing period trended favorably versus historical experience, supporting continued development of Fast Track-designated program.
  • Enrollment reached 250 patients in open-label non-HLA-A02 cohort, expanding treated-patient experience versus earlier mid-stage study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230600PRIMZONEFULLFEED9695688) on April 23, 2026, and is solely responsible for the information contained therein.